Department of Obstetrics & Gynecology, Drexel University College of Medicine, 216 North Broad Street, 4th Floor, Philadelphia, PA 19103, USA.
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, 703 19th Street South, ZRB 230, Birmingham, AL 35294-0007, USA.
Future Microbiol. 2018 Apr;13:507-524. doi: 10.2217/fmb-2017-0270. Epub 2018 Jan 12.
Secnidazole is a next-generation 5-nitroimidazole approved for more than three decades in Europe, Asia, South America and Africa and recently in the USA as a single-dose (2 g) treatment of bacterial vaginosis (BV). Secnidazole is characterized by potent in vitro antimicrobial activity against BV-associated pathogens, as well as prolonged terminal elimination half-life and systemic exposure. These characteristics form the basis of effective and safe treatment of BV with a 2-g single-dose secnidazole regimen, which was recently confirmed in double-blind, placebo-controlled clinical trials conducted in the USA. The option to treat BV with single-dose secnidazole not only cures the primary infection but also may diminish risks of serious sequelae of untreated or undertreated infection.
硝呋太尔是一种新一代的 5-硝基咪唑类药物，在欧洲、亚洲、南美洲和非洲已经获得批准使用超过三十年，最近在美国也被批准用于单剂量（2 克）治疗细菌性阴道病（BV）。硝呋太尔具有强大的体外抗微生物活性，针对与 BV 相关的病原体，以及延长的终端消除半衰期和全身暴露。这些特性构成了用 2 克单剂量硝呋太尔方案有效和安全治疗 BV 的基础，最近在美国进行的双盲、安慰剂对照临床试验中得到了证实。用单剂量硝呋太尔治疗 BV 的选择不仅可以治愈原发性感染，还可能降低未经治疗或治疗不充分的感染的严重后遗症的风险。
